Search results
Results from the WOW.Com Content Network
Template:Androgen replacement therapy formulations and dosages used in men; Template:Medications and dosages used in hormone therapy for transgender women; Template:Androgen replacement therapy formulations and dosages used in women; Template:Androgen/anabolic steroid dosages for breast cancer
Androgen replacement therapy formulations and dosages used in men Route Medication Major brand names Form Dosage Oral: Testosterone a – Tablet: 400–800 mg/day (in divided doses) Testosterone undecanoate: Andriol, Jatenzo: Capsule: 40–80 mg/2–4× day (with meals) Methyltestosterone b: Android, Metandren, Testred: Tablet: 10–50 mg/day ...
Androgen replacement therapy formulations and dosages used in men Route Medication Major brand names Form Dosage Oral: Testosterone a – Tablet: 400–800 mg/day (in divided doses) Testosterone undecanoate: Andriol, Jatenzo: Capsule: 40–80 mg/2–4× day (with meals) Methyltestosterone b: Android, Metandren, Testred: Tablet: 10–50 mg/day ...
Cyproterone acetate (CPA), sold alone under the brand name Androcur or with ethinylestradiol under the brand names Diane or Diane-35 among others, is an antiandrogen and progestin medication used in the treatment of androgen-dependent conditions such as acne, excessive body hair growth, early puberty, and prostate cancer, as a component of feminizing hormone therapy for transgender individuals ...
Template:Medications and dosages used in hormone therapy for transgender men References ^ Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG (November 2017).
Trestolone, also known as 7α-methyl-19-nortestosterone (MENT), is an experimental androgen/anabolic steroid (AAS) and progestogen medication which has been under development for potential use as a form of hormonal birth control for men and in androgen replacement therapy for low testosterone levels in men but has never been marketed for medical use.
The medication has been found to achieve 96.7% to 97.3% inhibition of aromatase at a dosage of 1 mg/day and 98.1% inhibition of aromatase at a dosage of 10 mg/day in humans. [ 4 ] [ 3 ] As such, 1 mg/day is considered to be the minimal dosage required to achieve maximal suppression of aromatase with anastrozole. [ 4 ]
Spironolactone also commonly and dose-dependently produces gynecomastia (breast development) as a side effect in men. [ 110 ] [ 129 ] [ 131 ] [ 132 ] At low doses, the rate is only 5 to 10%, [ 132 ] but at high doses, up to or exceeding 50% of men may develop gynecomastia.